BeyondSpring Inc. (BYSI)
BYSI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.6067
-1.43% on the day
Market cap
$24.9M
Nano cap
Revenue · 2025
$0
No prior year to compare
Net income · 2025
-$1.0M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1677940/000117184326001908/0001171843-26-001908-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BYSI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001677940 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$1.0M |
| Operating income | -$8.9M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.8M |
| Total assets | $25.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-29 |
| Latest annual report FORM 10-K | 10-K | 2026-03-25 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-10-13 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-09-03 |
Source: SEC EDGAR submissions feed, 263 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $5.18 | -4.95% | $24.7M |
| CNTX | Context Therapeutics Inc. | $0.2750 | -9.84% | $25.3M |
| MCRB | Seres Therapeutics Inc. | $2.53 | -5.60% | $25.4M |
| QNTM | Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $2.89 | +2.48% | $24.5M |
| ATOS | Atossa Therapeutics Inc. | $2.56 | +7.17% | $25.5M |
| PBM | Psyence Biomedical Ltd. Common Shares | $4.55 | -4.01% | $24.2M |
| ABVC | ABVC BioPharma Inc. | $0.9790 | -0.08% | $26.1M |
| KYNB | Kyntra Bio Inc. | $5.87 | -4.08% | $23.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier